GlobeNewswire PharmaOriginal article
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Data ReadoutPositive
AI Analysis
Summary
60 Degrees Pharmaceuticals announced minimum enrollment achievement in its hospitalized babesiosis trial with interim data expected by October 6, 2026.
Clinical Trial Data
Outcome Details
Minimum enrollment achieved for interim analysis
Importance:6/10
Sentiment:
0.50
clinical trialinterim datababesiosisenrollment
Read the original article
Published by GlobeNewswire Pharma on July 29, 2026 8:03 PM